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Abstract: Plasma hemopexin (HPX) is the key antioxidant protein of the endogenous clearance
pathway that limits the deleterious effects of heme released from hemoglobin and myoglobin (the
term “heme” is used in this article to denote both the ferrous and ferric forms). During intra-vascular
hemolysis, heme partitioning to protein and lipid increases as the plasma concentration of HPX
declines. Therefore, the development of HPX as a replacement therapy during high heme stress
could be a relevant intervention for hemolytic disorders. A logical approach to enhance HPX yield
involves recombinant production strategies from human cell lines. The present study focuses on
a biophysical assessment of heme binding to recombinant human HPX (rhHPX) produced in the
Expi293FTM (HEK293) cell system. In this report, we examine rhHPX in comparison with plasma
HPX using a systematic analysis of protein structural and functional characteristics related to heme
binding. Analysis of rhHPX by UV/Vis absorption spectroscopy, circular dichroism (CD), size-
exclusion chromatography (SEC)-HPLC, and catalase-like activity demonstrated a similarity to HPX
fractionated from plasma. In particular, the titration of HPX apo-protein(s) with heme was performed
for the first time using a wide range of heme concentrations to model HPX–heme interactions to
approximate physiological conditions (from extremely low to more than two-fold heme molar excess
over the protein). The CD titration data showed an induced bisignate CD Soret band pattern typical
for plasma and rhHPX versions at low heme-to-protein molar ratios and demonstrated that further
titration is dependent on the amount of protein-bound heme to the extent that the arising opposite CD
couplet results in a complete inversion of the observed CD pattern. The data generated in this study
suggest more than one binding site in both plasma and rhHPX. Furthermore, our study provides a
useful analytical platform for the detailed characterization of HPX–heme interactions and potentially
novel HPX fusion constructs.
Keywords: heme; hemopexin; circular dichroism; recombinant hemopexin
1. Introduction
Heme (iron-protoporphyrin IX) is transferred from extra-cellular hemoglobin (Hb)
into plasma proteins and lipids or tissues under numerous clinical conditions and medical
interventions [1–5]. Hemopexin (HPX) is an acute-phase plasma glycoprotein (~57 kD)
whose major physiological function is the binding and clearance of heme from the central
compartment. HPX binds heme with the highest affinity of any known protein (Kd < 1 pM)
to form a low-spin bis-histidyl HPX/heme equimolar complex, thus preventing heme trans-
fer and toxicological response, while facilitating cellular clearance and metabolism [6–10].
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HPX operates as a second line of endogenous defense against heme-mediated oxidative
stress following the depletion of haptoglobin by extra-cellular Hb [2,3,11,12].
The physiological plasma levels of HPX are reported to be 1–2 mg/mL [1]. How-
ever, under pathological hemolytic conditions, when the concentration of bioavailable
heme in the plasma exceeds circulatory binding capacity, HPX levels can become acutely
reduced [1,13–15]. Reduced plasma concentrations of HPX are associated with high plasma
levels of albumin-, apo-lipoprotein- and tissue-heme oxidation products in patients with
hemolytic disorders [16].
Therefore, HPX replacement therapy has been proposed as a promising approach
to control pathophysiology following high heme stress [4,17–22]. Currently, there are no
approved HPX-based therapeutic preparations available in the US, nor abroad. Early
development efforts have focused on plasma HPX; nonetheless, recombinant HPX versions
may offer cost-effective approaches to developing HPX and fusion-based HPX therapeu-
tics. The characterization and evaluation of the heme-scavenging potential of novel HPX
preparations compared to plasma HPX is essential to early development, prior to costly
animal and clinical studies. Several systems have been used to express human gene for
HPX; however, recombinant forms of HPX remain essentially uncharacterized, leaving
scientific gaps in our understanding of protein folding, heme binding, and structural
integrity after expression to allow for comparisons with plasma-derived HPX [12]. The
primary focus of the study presented herein is a biophysical assessment of heme binding
to recombinant human HPX (rhHPX) produced in an Expi293FTM (HEK293) mammalian
cell system compared to plasma HPX.
Our UV/Vis, circular dichroism (CD), size-exclusion chromatography (SEC), catalase-
like activity assay, and temperature-induced unfolding data demonstrated a close similarity
between rhHPX and its human plasma counterpart. However, a secondary focus arose
from results suggesting that our titration of rhHPX with heme revealed dramatic changes in
the protein-induced chirality profile. This experimental observation is strongly dependent
on the amount of protein-bound heme and prompted us to revisit heme interactions with
both plasma HPX and rhHPX in comparative experiments.
The heme-binding capacity of HPX was evaluated as one mole of heme per one mole
of HPX [23], which was further supported by a crystal structure of the HPX/heme complex
that revealed a high-affinity heme-binding site formed between two beta-propeller domains
of the protein [24]. Not surprisingly, only the preparation of stoichiometric 1:1 HPX/Heme
complexes are reported [24–32]; however, the equimolar complexes reveal a striking variety
of induced CD spectral data [32–35].
Within this component of the study, we performed a titration of rhHPX (as well as
plasma HPX) with heme across a wide range of ligand-to-protein molar ratios from 0.1 up
to 2.4. This approach differs from other CD studies that mainly characterized equimolar
complexes of heme (or mesoheme) with human, rabbit, or murine HPX that were prepared
by the incubation of protein and ligand (at an equimolar or higher heme content) followed
by dialysis to remove the excess ligand. The purpose here was to evaluate the pattern of
protein-induced CD of heme in rhHPX/Heme complexes that can be used as a reference
for the characterization of heme-binding studies. The data generated by the titration of
rhHPX and plasma HPX with heme, together with catalase-like activity, thermal unfolding,
and SEC-HPLC data, suggest that HPX interactions with heme are not limited to a single
heme-binding site, but rather suggest a secondary site of low affinity, which can bind an
additional amount of heme. The methodology developed in this study, and specifically
rhHPX/heme titration data with a characteristic induced CD pattern that strongly depends
on the heme level in the sample, may be applicable to evaluating the performance of novel
HPX constructs, as well as for a better interpretation of currently available data.
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2. Results and Discussion
2.1. Characterization of rhHPX
Prior to conducting heme-binding experiments, we evaluated rhHPX in comparison
with plasma HPX, which is used as a reference, for folding by far-UV CD (Figure 1) and
molecular integrity by SEC-HPLC (vide infra). As shown in Figure 1, rhHPX exhibits a
characteristic far-UV CD spectrum with a close similarity to that of plasma HPX showing a
strong negative extremum at 206 nm and a characteristic positive CD band at 231–232 nm.
The ellipticity at 231–232 nm is attributed to through-space interactions between the






Figure 1. Far-UV circular dichroism (CD) data for plasma hemopexin (HPX) and recombinant human
HPX (rhHPX). Overlay of far-UV CD spectra (A), rhHPX secondary structure estimates (B), and
temperature-induced unfolding (C,D) suggest a close folding similarity between rhHPX and its
plasma fractionated counterpart.
The far-UV CD spectra of plasma HPX and rhHPX (Figure 1A) were used to estimate
the protein secondary structure [43]. According to the percentage of secondary structure
elements we obtained by using CDPro/CONTIN (Figure 2B), the secondary structure of
both HPX and rhHPX is dominated by β-structures (57.3–57.6%) and demonstrates a low
content of α-helices (~7%), which is consistent with crystal structure data [24].
The similarity of rhHPX folding to that of plasma HPX was further supported by
thermal unfolding data (Figure 1C,D). Although the temperature-induced unfolding (melt-
ing) profiles recorded for rhHPX and plasma HPX are not identical, the melting points are
approximately 62 ± 0.5 ◦C, within accuracy of the experiments.
2.2. UV/Vis Titration
Interactions of plasma HPX and rhHPX with heme were investigated using UV/Vis
absorption spectroscopy and then by visible CD. Figure 2A shows UV/Vis differential
spectra for an 18 µM solution of rhHPX in phosphate buffer saline (PBS) recorded immedi-
ately after adding a 0.1-equivalent aliquot of heme. While the heme added to PBS alone is
characterized by a broad spectrum with a maximum absorption around 370 nm of decreas-
ing intensity (broken gray trace), the mixed sample rhHPX/Heme with ligand-to-protein
(molar) ratio (L/P) 0.1 immediately exhibits a sharp Soret band at 413.5–414 nm with an
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intensity that rapidly increases within a 10-min timeframe and minimal changes thereafter.
The titration of plasma HPX and rhHPX with heme was conducted in parallel. Each step of
the UV/Vis titration was monitored for at least 40 min to ensure that the ligand–protein
interaction reached completion. Figure 2B reflects similar dynamics for rhHPX/Heme com-
plexes with higher heme content (shown here for L/P 0.9) and demonstrates a characteristic
isosbestic point typical for UV/Vis spectral changes of each intermediate.
Figure 2. UV/Vis data for heme binding to rhHPX and plasma HPX. (A) Dynamics of heme binding
to rhHPX at ligand-to-protein ratio (L/P) 0.1 monitored during 10 min (gray dotted trace shows
heme in phosphate buffer saline (PBS) alone). (B) Time-course UV/Vis spectra of rhHPX/Heme at
L/P 0.9 collected during 10 min (overlaid with A). (C) The absorbance intensities at 414 nm of heme
complexes with rhHPX and plasma HPX plotted vs. L/P. Protein concentration for both rhHPX and
plasma HPX was 18 µM in PBS. All UV/Vis data were collected in differential form by measuring
spectra of mixed samples against respective 18 µM protein in a 10 mm path length cuvette. The
samples with the absorbance intensity at 414 nm exceeding the instrument absorbance accuracy limit
(higher than 2.4 OD) were measured in a 5 mm pathlength cuvette. (D) Monitoring stability of the
heme complexes with HPX and rhHPX by the Soret band intensity (shown for samples with L/P 1).
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UV/Vis titration data for HPX/Heme and rhHPX/Heme are summarized in Figure 2C
as the Soret band intensity versus heme content in the samples (up to L/P 2) showing
two different UV/Vis intensity slopes that demonstrate similar heme complex formation
with each protein. Similar UV/Vis titration profiles were earlier reported for rat, rabbit,
and human plasma-derived HPX preparations [23,37,44] indicating HPX heme-binding
capacity to be greater than an equimolar amount of heme.
Figure 2D illustrates the exceptional stability of rhHPX/Heme and HPX/Heme that
was evaluated by monitoring the Soret band intensities of protein/heme equimolar samples
during 10-day storage at room temperature.
2.3. Heme Transfer from Methemalbumin to HPX
The heme-binding properties of rhHPX were further studied in experiments to assess
heme transfer from the human albumin heme complex (methemalbumin) (HA/Heme at
L/P 1, λmax at 403 nm) to rhHPX. As reflected in Figure 3, heme transfer from methemalbu-
min to rhHPX began immediately after the addition of rhHPX to HA/Heme sample and
was observed as a sharp increase in the Soret band at a λmax at 413.5–414 nm.
Figure 3. UV-Vis spectra of heme transfer from methemalbumin (HA/Heme) to rhHPX monitored
for 10 min after adding rhHPX (light blue trace corresponds to 1 min, and red trace—to 10 min).
However, it takes approximately 24 h to reach the state of no further changes in the
absorption spectra of the mixed sample, similar to that reported for plasma HPX [6]. The
bathochromic shift of 11-nm in the λmax position, from 403 nm of HA/Heme to 414 nm
of HA/HPX/Heme mixed sample, indicates that rhHPX efficiently transfers heme from
methemalbumin to generate a stable rhHPX/Heme complex.
2.4. CD Titration
Heme interactions with plasma HPX and rhHPX were further investigated by CD spec-
troscopy in the wavelength range that would allow for monitoring of heme–protein com-
plex formation, i.e., by monitoring the induced Soret band CD changes (350–500 nm). Por-
phyrins are powerful and highly sensitive chromophores that are exceptionally amenable to
CD spectroscopy analysis because of the intensities of chromophoric absorption facilitated
by their high extinction coefficients [45–48]. The Soret band region of the CD spectrum
provides the most informative insight into the heme interactions with HPX at the protein
binding site(s). Heme is an achiral molecule, and as an optically inactive compound, it does
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not exhibit any significant CD signal of its own. However, being situated in the protein
binding site, heme behaves as an optically active compound (a phenomenon of protein-
induced chirality). Protein-bound heme may exhibit a prominent Cotton Effect (CE) in the
region of the Soret band and some optical activity in the visible range. Optical activity in
the Soret region of hemoproteins occurs based on the coupling of the heme ππ* electronic
dipole transition moments with those of proximate aromatic amino acid residues (mainly,
Trp) of the protein matrix and heme distortions from planarity [49–51]. The origin of the
optical activity in the Soret region has been extensively investigated [52–55]. Therefore,
characteristic induced CD (ICD) spectra of hemoproteins (e.g., hemoglobin, myoglobin) or
other heme-binding proteins are indicative of nonplanar distortions of the heme and its
association with protein.
Heme equimolar complexes with HPX (rabbit, rat, and human) are well assessed by
Soret CD [26–32], yet there are discrepancies in the CD data across these studies. Along
with monophasic (monolobe) ICD [33], various biphasic (also called bisignate or bilobe)
ICD spectra were published for heme complexes with plasma HPX [32,34,35].
The intriguing fact that a single heme-sited HPX [24] exhibits a strong bisignate
CD related to the Soret band has been a point of discussion and debate. According to
one plausible interpretation, human plasma HPX preparations are comprised of two
spectroscopically distinct, non-interconverting HPX forms that exhibit characteristically
different Soret CD spectra, which superimposition is observed as a bisignate spectrum [35].
In general, bisignate ICD spectra observed for a single heme-liganded HPX can be explained
via an exciton coupling between two or more chromophores that may occur in the case
of HPX dimerization and/or aggregation or using heme stock solutions containing heme
dimers/aggregates.
Figure 4A shows the CD titration of rhHPX with heme in a low L/P range, which was
performed with starting heme content in the sample as low as 0.05 molar equivalent relative
to the rhHPX concentration to specifically evaluate whether it may result in a monolobe
single-CE CD spectrum, which is expected from a protein with a single heme-binding
site. However, even heme binding at this low ligand-to-protein ratio did not produce a
clear monolobe CD, showing the first positive CE at 420 nm and indication of a weak
second CE around 404 nm (blue trace). At a 1:10 (L/P 0.1) heme-to-protein stoichiometry,
the bisignate ICD pattern is clearly observed. Further rhHPX titration with heme (shown
here up to an L/P of 0.5) resulted in a proportional increase of the ICD intensities at
420 nm (1st positive CE) and at 404 nm (2d negative CE) that could be explained by
exciton coupling between heme bound to rhHPX at two sites. It is noteworthy that all
six CD spectra shown on plot A intercept at an identical isosbestic point (411–412 nm)
in good correlation with the Soret band absorption λmax, which is in accordance with
the exciton coupling theory [45,46,48]. However, the bisignate ICD pattern could also
be interpreted because of heme binding to two distinct forms of protein as proposed for
human plasma HPX [35]. We certainly expected that exploring a recombinant platform
must result in a uniform recombinant protein and exclude a possibility of protein isoforms
with differing conformational arrangement for heme binding. Nevertheless, these titrations
of rhHPX and plasma HPX were performed in parallel and demonstrate similar bisignate
CD titration patterns. Figure 4B shows an overlay of ICD spectra for rhHPX/Heme and
plasma HPX/Heme (both at an L/P 0.4) to illustrate a close similarity observed for the
titration intermediate samples. Figure 4C provides a comparative summary for rhHPX and
plasma HPX titration with heme at relatively low heme-to-protein ratios, demonstrating
the similarity between the two proteins and an almost linear increase in the intensities
of positive and negative ICD bands at 420 nm and 404 nm versus the content of heme in
the samples.
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Figure 4. The CD titration of rhHPX and plasma HPX with heme in a low L/P range (from 0.05 to
0.5) shows closely comparable patterns: (A) Plasma HPX; (B) Induced CD for heme complexes with
plasma HPX and rhHPX of the same L/P are similar (shown for L/P 0.4). (C) The intensities of the
1st CE (420 nm) and 2nd CE (404 nm) plotted versus L/P values up to 0.5 for rhHPX/Heme (dark
blue and purple circles, respectively) and plasma HPX/Heme (respective lighter shades).
Further CD titrations of rhHPX and plasma HPX with heme at higher heme-to-protein
stoichiometric values (Figure 5) demonstrate dramatic ICD spectral changes related to
the protein-bound chromophore. Figure 5A shows an overlay of the visible ICD spectra
typical for rhHPX and plasma HPX with an increasing heme content in the titration
samples (from an L/P 1.0 to 2.4; for clarity, only selected spectra are shown). First, it is
noteworthy that all ICD spectra in the Soret region intercept through a classic isosbestic
point, which is consistent with a Soret λmax in the absorption spectra (414 nm). Second,
the changes reflected by the ICD spectra for the samples with higher than equimolar
heme content and the entire titration pattern (Figure 5A) differ from that observed at the
lower heme content (Figure 4A) and demonstrate an inversion of the CD titration pattern
per the increasing content of protein-bound heme. The most critical changes in the ICD
spectra are observed for heme–protein samples as the ratio of L/P exceeds 1:1, which is
visualized as complementary UV/Vis and CD spectra for the samples at an L/P of 1.0,
1.2, and 1.4 (Figure 5B,C). As shown in Figure 5B, an increase in heme content resulted
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in significant Soret CD changes with complete inversion of the bisignate ICD spectrum
from the 1st positive (420 nm)/2nd negative (400 nm) blue trace at an L/P of 1.0 to the
1st negative/2d positive (green) trace at an L/P of 1.4 through an intermediate state (orange
trace, L/P of 1.2). In the meantime, the complementary UV/Vis spectra reflected only
relatively small increase of the Soret band absorbance intensity (Figure 5C).
Figure 5. CD titration data for rhHPX and HPX with heme at higher than equimolar L/P. (A) Overlay
of the induced CD (ICD) spectra of the rhHPX/Heme samples (L/P 1.0–2.4; for clarity, selected spectra
are shown); (B) ICD spectra of rhHPX/Heme samples at L/P 1.0, 1.2, and 1.4, and (C) complementary
UV/Vis spectra; (D,E) ICD spectral changes plotted as the observed 1st CE and observed 2nd CE
versus increasing content of heme (L/P), respectively, for rhHPX (D) and plasma HPX (E).
A transition through an intermediate state with a shortened ICD amplitude (orange
trace) and an inverse +/− ICD couplet is indicative of a strong opposite exciton coupling
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phenomenon with the 1st negative/2nd positive CEs. The ICD spectra at an L/P of
1.2 and 1.4 with changes in the ICD amplitude and signs are likely observed due to a
superimposition of two opposite bisignate spectra.
Between an L/P of 1.4 and 2.4, the observed 1st negative/2nd positive ICD couplet
strongly increased to a nearly conservative ICD spectrum. In comparison with the ampli-
tude of the ICD associated with an L/P of 1.0, the magnitude of ICD amplitudes observed
for the samples of a higher L/P (2.0 and 2.4) is indicative of a strong exciton coupling,
suggesting an interplay between at least two heme chromophores.
To illustrate the inversion of the ICD pattern due to an arising opposite ICD couplet
per the increased heme content in the samples, Figure 5D,E shows CD titration data
plotted as the observed 1st CE and observed 2nd CE versus L/P for rhHPX and plasma
HPX, respectively.
To the best of our knowledge, CD titrations have not been performed in any studies
that would allow for an assessment of ICD changes dependent on the amount of protein-
bound heme. By evaluating a wide range of heme-to-protein molar ratios (from as low as
0.05 to more than a two-fold molar excess), we approximate HPX interactions that may
occur over a wide range of heme plasma concentrations consistent with those observed in
health and disease. We believe that the Soret CD data collected for HPX–heme interactions
at increasing heme concentrations, the differences defined between the data related to
low and high heme concentration ranges, and the intriguing inversion of the ICD couplet
suggest a novel complexity of heme’s interactions with HPX. The induced CD changes
observed during HPX titration with heme are very likely the result of a few contributions
from more than one heme chromophore in different protein chiral environments. From an
analytical perspective, the bisignate positive/negative ICD pattern at the low L/P range,
the inversion of the bisignate ICD at an L/P ratio greater than equimolar, along with the
magnitude of the CD amplitude introduce novel findings. Since the observed changes are
unambiguously dependent on the amount of HPX-bound heme, they can be best explained
by exciton coupling between two identical heme chromophores on one HPX molecule.
Whether the observed strong CD couplet can be caused by the exciton interaction
between hexa-coordinated low spin heme at the HPX primary binding site (which must be
fully saturated at this level of the ligand) with the unbound heme or loosely associated at
the protein surface is a very unlikely possibility, because to enable a strong through-space
dipole–dipole interaction the chromophores must be properly oriented with respect to each
other [45,46].
2.5. Heme Accessibility to Hydrogen Peroxide
We examined the rhHPX/Heme and HPX/Heme complexes for heme accessibility to
hydrogen peroxide (H2O2) by using catalase-like activity assay, as described earlier [56]. As
shown in Figure 6A for rhHPX/Heme and HPX/Heme complexes at an L/P of 0.8, the Soret
band intensity at 414 nm was not affected up to 8-fold molar excess of H2O2, suggesting
that the complexes remained stable and protein-bound heme was not being degraded. This
observation is consistent with the biochemical interaction where HPX binds and locks heme
in a bis-histidyl tweezer-fixed conformation, and the hexa-coordinated low spin heme is
oxidatively inert and cannot interact with prooxidants, such as H2O2 [10,57]. However,
heme accessibility to H2O2 in the complexes at higher L/P ratios demonstrated differing
behavior. Figure 6B shows time-course measurements of heme complexes at an L/P of 2.0
in the presence of the same 8-fold access of H2O2. Prior to adding H2O2, the samples were
subjected to Amicon filtration to remove any possible non protein-bound heme.
The decline in the Soret band intensity is observed for both samples (B), but it is
considerably different from that of heme in PBS alone (gray trace). These data are indicative
of some heme bound to a protein low affinity secondary binding site in which heme is
less protected, more accessible to the external environment, and therefore able to interact
with H2O2.
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Figure 6. UV-Vis time-course measurements of heme complexes with plasma HPX and rhHPX in
the presence of H2O2 (8-fold molar excess over the protein/heme complex) at an L/P of 0.8 (A) and
2.0 (B) versus heme in PBS alone.
2.6. Temperature-Induced CD Assessment
A temperature-induced CD study was performed to examine whether the conforma-
tional stability of rhHPX/Heme may differ from that of the recombinant protein apo-form
(Figure 7). The ellipticity of samples was monitored at two wavelengths, 206 nm and
231 nm, within a temperature range spanning from 20 to 90 ◦C. Figure 7 shows the thermal
unfolding (melting) data collected for protein apo-forms and heme-complexes at the wave-
length 231 nm, which is usually regarded as a sensitive and reliable reporter of the HPX
tertiary structure [37–41].
Figure 7. Temperature-induced CD changes: (A) Plasma HPX and HPX/Heme at an L/P of 1.0 and
(B) rhHPX and rhHPX/Heme at an L/P of 1.0.
Temperature-induced CD data suggest that heme binding to rhHPX stabilizes the
protein structure as indicated by a Tm = 71 ± 0.5 ◦C observed for the rhHPX/Heme complex
(L/P of 1.0) in comparison with that of apo rhHPX (Tm = 62 ± 0.5 ◦C). Although the CD
melting profiles for the recombinant and plasma samples are not identical, the melting
points of the complexes approximate each other. In comparison with the data collected
for apo-proteins, these results demonstrate that both rhHPX and plasma HPX are largely
stabilized by bound heme. The Tm values determined here for plasma apo HPX and
HPX/Heme appear to be slightly different than values obtained using differential scanning
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calorimetry [38]; nonetheless, our data are comparable to the Tm values determined by
Rosell et al. from their temperature-induced CD study [58].
2.7. SEC-HPLC Assessment
SEC-HPLC was employed in this study to examine the molecular integrity of the
recombinant and plasma HPX apo-forms and HPX-heme complexes at various L/P ratios.
The SEC data shown in Figure 8A demonstrate overlapping rhHPX and plasma HPX
peaks in the representative chromatograms, with retention times 19.8 min and 19.7 min,
respectively. However, the elution of rhHPX was accompanied by a small peak with a
retention time 22.2 min that was considered a protein impurity visualized at a protein
detection wavelength of 280 nm. The intensity of this small peak did not increase or change
per rhHPX binding with heme, suggesting a small non-heme binding impurity. According
to the chromatograms overlaid in Figure 8B, the elution times of plasma HPX/Heme
complexes of various heme content (shown for an L/P of 0.5 and 2.0) do not differ from
that of plasma HPX apo-form. The same is shown for the respective rhHPX samples
(plot C). In addition, Figure 8C provides an overlay with a chromatogram of a pegylated
form of HPX (PEG-HPX), which we used as a reference high molecular weight sample
to visualize a range (10 to 20 min) of possible heme-induced protein aggregation. Based
on the SEC-HPLC data, no oligomers were identified for the rhHPX and HPX complexes
with heme. This is consistent with earlier observations that heme binding to HPX did not
prompt an aggregation [37,59]. Based on this observation, the possibility of heme-induced
aggregation, which might be an alternative cause of bisignate CD patterns and/or inversion
of the CD pattern (vide supra) is unlikely. Moreover, under SEC-HPLC conditions, any heme
excess loosely associated with either rhHPX or plasma HPX is expected to be removed
from the complexes; therefore, from a peak height or area quantitation corresponding to
rhHPX/Heme at an L/P of 0.5 and 2.0 samples estimates of approximately a 1.5-fold molar
equivalent of heme remain bound within the rhHPX/Heme sample. This contrasts with
the expected equimolar L/P ratio and is suggestive of an additional, but likely low affinity
heme binding site.
There remains the possibility that the characteristic bisignate ICD profile observed
from the very first steps of HPX titration with heme may be caused by the dimeric state of
the heme stock solution in DMSO (or NaOH) aliquots that were used for the HPX titration.
Nonetheless, this scenario seems unlikely because similar heme stock solutions and aliquots
were used in primary titration steps for human albumin and α1-microglobulin, both of
which demonstrate a traditional one chromophore—one major Cotton Effect CD profile [56].
Future work should consider a thorough interpretation of the discrepancies between the
crystal structure, establishing a single heme binding site, and the observed bisignate CD
spectral data, which may be achieved using specifically designed HPX mutants.
The purpose of our study was to characterize rhHPX produced in the Expi293FTM
mammalian cell system for the interaction with heme and use this data as a reference for
later experiments that evaluate novel HPX constructs (e.g., fusion proteins). Unlike previ-
ous CD studies that mainly characterized equimolar HPX-heme mixtures, we performed a
titration of rhHPX (as well as plasma HPX) with heme across a wide range of the ligand
concentrations, from the ligand-to-protein molar ratio 0.1 up to 2.4. The purpose was to
evaluate the pattern of protein-induced CD of heme in rhHPX/Heme complexes that can be
used as a reference for the characterization of heme binding to novel fusion HPX complexes
that may exhibit a greater capacity for the ligand than HPX alone. Our thermal unfolding
study demonstrated that heme binding stabilizes the protein structure (Tm 71 ± 0.5 ◦C vs.
62 ± 0.5 ◦C). The data generated by the titration of rhHPX and plasma HPX with heme,
together with catalase-like activity and SEC-HPLC data, first demonstrate that rhHPX and
plasma-derived HPX behave similarly, and second, that HPX interactions with heme are
not limited to a single heme-binding site within the HPX plasma or recombinant forms.
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Figure 8. SEC-HPLC assessment: (A) Apo-proteins rhHPX and HPX; (B) HPX/Heme samples at an
L/P of 0.5 and 2.0 vs. HPX; (C) Heme complexes with rhHPX (L/P of 0.5 and 2.0) vs. rhHPX and
PEG-HPX. Detection of the peaks was performed at 280 nm and 413 nm as specified on the plots.
According to the crystal structure, heme binds to HPX in a bis-histidine hexa-coordinated
ligation mode being captured between His-213 and His-226 residues. The possibility of
other heme-binding sites has been considered, partly based on molecular modeling, but
it has been limited to an alternative heme-binding site of the highest heme-binding affin-
ity [24,60]. Thus, a pair of His-82 and His-127 at the broader end of the central tunnel has
been discussed [24,60]. Heme binding to this plausible site was logically proposed to occur
in a bis-histidyl ligation mode. However, the data from amino-acid sequence homology
comparisons of HPXs from different vertebrate species, as well as site-directed mutagen-
esis studies suggest that there is only one invariant His (i.e., His-127) residue capable of
acting as a heme-accepting site [60]. Cox et al. also demonstrated that the environments
of at least four of five His residues are perturbed by heme binding, and that the heme
environments of intact HPX and domain I are not identical. Therefore, to further discuss
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the data generated in our study suggesting a secondary heme-binding site, we consider
His-127 is a plausible residue for a non-bis-histidyl interaction as a secondary binding site
of lower affinity. We speculate that a weaker ligation of heme to His-127 in coordination
with other amino acid residues could reasonably account for our observations. Our data
support a secondary site of low affinity, which can bind an additional amount of heme, thus
enabling a strong exciton coupling between the heme chromophores. The methodology
developed in this study, and specifically rhHPX/heme titration data with a characteristic
induced CD pattern, which strongly depends on the heme concentration in the sample,
are essential for interpretation of already reported data and for the characterization of
novel HPX constructs. Further research will help to refine our conclusions and foster
interpretations of the intriguing interactions between heme and HPX variants.
3. Material and Methods
3.1. Materials
Hemin, dimethylsulfoxide (DMSO), and hydrogen peroxide (H2O2) were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Phosphate buffer saline (PBS) 10X (0.1 M
phosphate buffer with 27 mM KCl and 1.37 M NaCl, pH 7.4) and deionized water were
from GE Healthcare (Piscataway, NJ, USA). Buffers for rhHPX affinity purification were
based on phosphate (20 mM) containing NaCl (500 mM) and increasing amounts of imida-
zole for equilibration (10 mM), washing (25 mM), and elution (500 mM). Size exclusion
chromatography (SEC) was performed using PBS as mobile phase. Other chemicals used
in this study were analytical grade from Fisher Scientific (Fair Lawn, NJ, USA).
3.2. Generation of rhHPX Expression Plasmid and Transient Transfections
A cDNA encoding human hemopexin (Genbank accession number NP_000604) was
codon-optimized for human expression and synthesized by Geneart® (Invitrogen™, Thermo
Fisher Scientific, Waltham, MA, USA) with a Kozak consensus sequence [61] (GCCACC)
immediately upstream of the initiating methionine (+1) and ligated into pcDNA3.1 (Invit-
rogen™, Thermo Fisher Scientific). Large-scale preparations of plasmid DNA were carried
out using QIAGEN Plasmid Giga Kits (12191) according to the manufacturer’s instructions.
The nt sequences of the plasmid construct was verified by sequencing both strands using
BigDye™ Terminator Version 3.1 Ready Reaction Cycle Sequencing (Invitrogen™, Thermo
Fisher Scientific.4337455) and an Applied Biosystems 3130xl Genetic Analyzer.
Transient transfections of the rhHPX expression plasmid using Expi293F™ cells were
performed using Expifectamine™ transfection reagent (Invitrogen, Life Technologies, Carls-
bad, CA, USA) according to the manufacturer’s instructions. Cells were transfected at a
final concentration of 1 × 106 viable cells/mL and incubated in a shaking incubator for
6 days at 37 ◦C in 8% CO2. Pluronic F68 (GIBCO, Life Technologies), to a final concentration
of 0.1% v/v, was added 4 h post-transfection. At 24 h post-transfection, cell cultures were
supplemented with LucraTone Lupin (Millipore, Billerica, MA, USA) to a final concen-
tration of 0.5% v/v. The cell culture supernatants were harvested by centrifugation at
2500 rpm and then were passed through a 0.45µm filter (Nalgene, Rochester, NY, USA)
prior to purification.
3.3. Purification of rhHPX
rhHPX expressed using the Expi293F™ Expression System was subjected to an au-
tomated 2-step purification protocol on an ÄKTA Express system operated by Unicorn
software (GE Healthcare, Milwaukee, WI, USA). The purification protocol was based on
the described strong interaction of HPX with bivalent metal affinity chelate resins even in
the absence of a His-Tag [34]. Briefly, 2 L of filtered conditioned media containing rhHPX
was pre-concentrated to 220 mL using a tangential flow filtration system (ÄKTA Crossflow,
GE Healthcare, Milwaukee, WI, USA) equipped with a 30 kDa cut-off membrane. The
retentate was buffer-exchanged into PBS to overcome the potential interference of the
Expi293 media components with the IMAC matrix. Then, conditioned media was loaded
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at 0.3 mL/min onto an equilibrated His-Trap column (5 mL, GE-Healthcare) followed
by sequential washing with equilibration buffer and wash buffer at 0.5 mL/min. Bound
rhHPX was eluted using elution buffer and further purified by SEC using a Superdex200
26 × 60 column (ÄKTA Crossflow, GE Healthcare, Milwaukee, WI, USA) equilibrated
with PBS. The main peak was collected and concentrated to 10.5 mg/mL using an Amicon
Ultra-15 Centrifugal Ultracel 10K filter (Millipore, Darmstadt, Germany) according to the
manufacturer’s instructions. The concentration of the purified rhHPX was measured using
the Trinean DropPlate system as previously described [62], and the purity of rhHPX was
confirmed by analytical SEC and SDS-PAGE.
3.4. PEG-HPX Preparation
PEG-HPX was prepared from plasma-derived HPX provided by CSL Behring, Kanka-
kee, IL, USA. HPX was further modified using Maleimide NHS-activated PEG (Thermo
Fisher Scientific, Basel, Switzerland) according to the manufacturer’s instructions. The ap-
proximate weight range (120–180 kDa) was determined by size exclusion chromatography.
3.5. Stock Solutions of Heme, rhHPX, and Plasma HPX
Heme stock solutions in DMSO (1.4 mM and 0.7 mM) were freshly prepared prior to
use, purged with argon, and kept protected from light. The heme concentrations in the stock
solutions were determined spectrophotometrically using heme molar extinction coefficient
of 170,000 M−1 cm−1 at λmax 404 nm [63]. Stock solutions of apo-proteins (plasma HPX
and rhHPX) were prepared in PBS, pH 7.4, and diluted to a concentration of 19 µM (for
heme-binding experiments) or 4 µM (for far-UV CD assessment). Protein concentrations
were measured spectrophotometrically using extinction coefficient of 120,000 M−1 cm−1 at
280 nm published for human apo-HPX [64].
3.6. Titration of Plasma HPX and rhHPX with Heme
Titration of each apo-protein with heme was performed using 19 µM rhHPX (or plasma
HPX) samples in PBS. Calculated aliquots of heme stock solution in DMSO (0.7 mM—for
low L/P range, and 1.4 mM—for higher L/P range) were added stepwise to 1.5 mL of
each protein solution in a 10 mm pathlength quartz cuvette. Each solution was gently
mixed (by turning the cuvette upside-down), followed by UV/Vis and CD monitoring
until no significant spectral changes indicate a completion of the protein/heme interactions.
The complementary CD and UV/Vis spectra were collected (for each L/P step), followed
by addition of the next heme increment, and so on. During titration, the samples were
maintained at 20 ± 1 ◦C, protected from light, and flashed by argon. Initial apo-protein
stock solutions served as a blank in spectral measurements. A total amount of DMSO in
the titration samples did not exceed 4% v/v.
3.7. UV/Vis Measurements
UV/Vis electronic absorption measurements were performed on an Agilent HP 8453
UV-visible spectrophotometer (Agilent Technologies Deutschland GmbH, Waldbronn,
Germany) at 25 ± 0.2 ◦C in a wavelength range 250–700 nm using a quartz cuvette of 1 cm
pathlength. The HPX/heme titration samples with absorbance intensity close to or beyond
the instruments upper limit (2.4 OD) were measured in a 5 mm pathlength quartz cuvette,
and the results were doubled. To collect for UV/Vis differential spectra of the HPX/heme
complexes, the apo-protein sample (rhHPX or plasma HPX) was first measured as a blank.
3.8. CD Measurements
CD measurements were performed on a Jasco J-815 Spectropolarimeter (JASCO Co.,
Tokyo, Japan) at 25 ± 0.2 ◦C and the temperature was maintained by a Peltier thermostat.
The spectra were measured in triplicate with a scan speed of 100 nm/min, bandwidth
of 1.0 nm, and resolution of 0.2 nm. The far-UV CD spectra were recorded between 180
and 260 nm in a 1 mm quartz cuvette. Protein concentration in the samples for far-UV
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CD was 4.5 µM in PBS, pH 7.4. The baseline was subtracted by using PBS as a blank. The
unsmoothed CD spectra of protein samples were converted into ∆ε and analyzed for the
secondary structure elements using CDPro/CONTIN.
The induced CD spectra of rhHPX and plasma HPX titration with heme were recorded
between 300 and 650 nm in a rectangular quartz cuvette with 1 cm pathlength. Induced
CD was determined as the CD of the protein–heme sample measured versus protein alone
as a blank. The volumes, protein final concentration (18 µM), and the content of DMSO
(4%) for all samples were kept constant. An ellipticity of CD spectra was expressed in
millidegrees (mdeg).
Temperature-induced conformational changes were assessed for rhHPX, HPX, and
the respective heme-protein L/P 0.9 complexes at the protein concentration approximately
4.5 µM in PBS, pH 7.4. The ellipticity at 231 nm was recorded as a function of temperature
from 20 to 90 ◦C with a temperature increase 2 ◦C/min as controlled by the Peltier device
connected to a Jasco J-815 spectropolarimeter.
3.9. Stability to Hydrogen Peroxide
An aliquot of H2O2 solution was added to a 1 mL sample of 19 µM rhHPX/Heme or
HPX/Heme (L/P 0.8) to create 8-fold molar excess over the complex, and the mixture was
immediately monitored by UV/Vis for 10 min at room temperature. The rhHPX/Heme
or HPX/Heme complexes at an L/P of 2.0 were first subjected to two rounds of Amicon
3K filtration, followed by Soret band absorption measurements and then treated with
H2O2 using the same procedure. A reference heme sample in PBS was freshly prepared
(due to limited stability in aqueous solutions) and adjusted to ~0.6 OD at λmax 363 nm.
After mixing with an aliquot of H2O2 (8-fold excess), the sample was immediately UV/Vis
monitored. The time-course UV/Vis measurements were taken at room temperature in
a 10 mm pathlength quartz cuvette at the following time points: 30 s, 1, 2, 4, 6, 8, and
10 min. The concentration of H2O2 was determined spectrophotometrically as described
elsewhere [65].
3.10. SEC-HPLC
Molecular integrity was evaluated by using a BioSep-SEC-s3000 (600 × 7.5 mm)
column (Phenomenex, Torrance, CA, USA) connected to a Waters 2535 Quaternary Gra-
dient Module pump and Waters 2998 Photodioide Array Detector controlled by a Waters
600 controller using Empower 2 software (Waters, Milford, MA, USA). Mobile phase: 1 mM
potassium phosphate (K2HPO4/KH2PO4) pH 7.4. The injection volume of each protein
solution was 50 µL. Detection was performed at three wavelengths: 280, 404, and 414 nm.
4. Conclusions
In this study, we characterized rhHPX for heme binding using different analytical
techniques in comparison with plasma-derived HPX. Heme–protein interactions were
evaluated across a wide range of heme concentrations from a ligand-to-protein molar ratio
0.1 up to 2.4 to make the outcomes of this study useful for the evaluation of heme binding
to HPX-fusion proteins produced in the same system. Our UV/Vis, CD, SEC-HPLC, and
catalase-like activity assay data demonstrated a close similarity between rhHPX and the
plasma counterpart. Thermal unfolding studies demonstrated that heme binding greatly
stabilizes the protein structure. The induced CD data revealed dramatic Soret CD changes
that are dependent on the amount of protein-bound heme. These data suggested that HPX
interactions with heme are not limited to a single heme-binding site. The data generated in
this study provide a novel interpretation of heme interactions with HPX and offer a unique
understanding of HPX-ligand binding reported on for the first time. We further suggest
that the techniques reported herein provide a useful strategy to evaluate heme binding in
novel HPX constructs.
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